Phase 2 Epilepsy trials recruiting now

All Epilepsy trials, every phase

Other phases for Epilepsy

Phase 2 Epilepsy trials

• A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
  NCT05419492 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 14 locations
• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
  NCT07227857 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 12 Years · Sex: All (male and female) · 15 locations
• A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
  NCT07219407 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 7 locations
• A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
  NCT06422923 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
  NCT06609889 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 18 Years · Sex: All (male and female) · 1 location
• A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
  NCT06388707 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
  NCT06769659 · Phase: Phase 2 · Ages: 16 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
  NCT06132893 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 124 locations
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
  NCT07600736 · Phase: Phase 2 · Ages: 1 Month to 21 Years · Sex: All (male and female) · 1 location
• A Study to Prevent Infantile Spasms Relapse
  NCT06819670 · Phase: Phase 2 · Ages: 2 Months to 18 Months · Sex: All (male and female) · 1 location
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 36 locations
• ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
  NCT07531745 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 12 Years · Sex: All (male and female) · 6 locations
• Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
  NCT04063540 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 10 locations
• An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
  NCT06908356 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 11 locations
• An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
  NCT07238868 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• BMB-101 in Absence Epilepsy and DEE
  NCT06401538 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 5 locations
• Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
  NCT05637086 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial
  NCT07747324 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
  NCT06483061 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Exogenous Ketone Esters for Drug Resistant Epilepsy
  NCT05670847 · Phase: Phase 2, Phase 3 · Ages: 1 Year to 16 Years · Sex: All (male and female) · 1 location
• Exogenous Ketone Esters for Refractory Status Epileptics
  NCT05674552 · Phase: Phase 2, Phase 3 · Ages: 1 Year to 10 Years · Sex: All (male and female) · 1 location
• Glutamate Inhibitors in Glioblastoma
  NCT05664464 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder
  NCT07102524 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 20 Years · Sex: All (male and female) · 1 location
• Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
  NCT05431595 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)
  NCT07095842 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 16 Years · Sex: All (male and female) · 1 location
• RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
  NCT06798896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
  NCT07141329 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
  NCT05518578 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 10 locations
• Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
  NCT06590896 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 29 locations
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · 22 locations
• The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
  NCT05019885 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.
  NCT07363603 · Phase: Phase 1, Phase 2 · Ages: 1 Year to 14 Years · Sex: All (male and female) · 1 location
• Treatment of Refractory Infantile Spasms With Fenfluramine
  NCT04289467 · Phase: Phase 2 · Ages: 12 Months to 36 Months · Sex: All (male and female) · 2 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.